Medicines Company Gets Aggressive With Inclisiran Phase III Plans

 
• By Alexandra Shimmings

Updated ORION-1 data presented at the European Society of Cardiology have encouraged The Medicines Company to take an "aggressive" approach to its Phase III plans for the novel PCSK9 synthesis inhibitor.

Night sky
Aiming for the stars • Source: Shutterstock

More from Clinical Trials

More from R&D